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Introduction
Pancreatic ductal adenocarcinoma (PDAC) is a major unsolved health problem, with less esent with advanced disease (i.e., locally-advanced or metastatic) at diagnosis. The primary goals of treatment in this setting are survival prolongation and palliation, but PDAC is notoriously resistant to systemic treatments [1] .
Identification of key factors to select patients with the highest likelihood of responding, while minimizing useless and toxic treatments, is urgently needed. Several genetic alterations have been associated with PDAC aggressive behaviour and chemoresistance [2] , while epigenetic factors recently emerged for their roles in tumor progression. In this context, Enhancer of Zeste Homolog 2 (EZH2) is becoming increasingly acknowledged as a prognostic biomarker in radically-resected PDAC patients [3] .
EZH2 is a catalytic subunit of the Polycomb group (PcG). PcG proteins can repress gene expression by forming multiple complexes leading to histones methylation, thus resulting in epigenetic control of gene expression [4] . In particular, EZH2 can silence several tumor suppressor genes by trimethylation at lysine 27 of histone H3, playing a key role in tumor development [5] . Furthermore, EZH2 is crucial for cancer stem cells self-renewal in several cancer types [6] , including PDAC, where EZH2 overexpression has been associated with decreased E-cadherin expression, invasion and poor prognosis [3, 7] . EZH2 is also an important factor in PDAC cell chemoresistance, since EZH2 depletion by RNA interference or inhibition by DZNep sensitized PDAC cells to gemcitabine [7, 8] .
Therefore, our study was aimed at evaluating the prognostic value of EZH2 expression in the subset of locally-advanced or metastatic PDACs. Moreover, since (1) blood samples are much more easier to obtain, especially for advanced cancers, and (2) recent studies suggested a role for candidate polymorphisms of EZH2 in lung cancer risk and colorectal cancer prognosis [9] [10] [11] , we performed a pharmacogenetic study of two candidate EZH2 polymorphisms.
The EZH2 gene contains 20 exons, 19 introns [12] , and 41 identified single nucleotide polymorphisms (SNPs), and encodes two isoforms of different transcript size [9] . Among these SNPs, we selected rs6950683 and rs3757441 because individuals carrying C/C alleles at these two SNPs have a lower risk of lung cancer than those carrying the T/T wild-type allele [9] . Rs3757441 is an intronic polymorphism, and might affect gene expression through several mechanisms, including changes in transcription-factor binding sites, splicing variants and microRNA (miRNA) targeting sequences. Rs6950683, is located upstream of exon 1, and, therefore, may impact gene expression by affecting the function promoter. Although the functional role of rs6950683 and rs3757441 has not yet been tested in experimental models [13] , a recent study in 220 patients affected by hepatocellular carcinoma, and 552 cancer-free controls, demonstrated that the individuals carrying at least one C allele at rs6950683 and rs3757441 had a significantly lower risk of developing hepatocellular carcinoma than wild-type (T/T) individuals [14] .
Therefore we studied whether the EZH2 rs6950683 and rs3757441 might influence EZH2 expression and predict outcome, using several cohorts of locally-advanced or metastatic PDACs.
Materials and methods

Patients
EZH2 mRNA, protein levels and polymorphisms were evaluated in a first cohort of 32 out of the 36 locally-advanced or metastatic PDACs patients enrolled in a retrospective study on determinants of gemcitabine activity [15] . Patients' characteristics are described in the Supplemental Table S1 .
RNA and DNA were extracted from laser-microdissected biopsies, obtained before chemotherapy, using the LMD7000 instrument (Leica-Microsystems, Wetzlar, Germany), as described previously [16] . The laser-microdissection procedure adopted in this study and the methods used to validate the purity of our PDAC samples are discussed in the "Supporting information".
To validate the data of EZH2 expression of the first cohort we selected a second cohort of 25 metastatic PDAC (Supplemental Table S1 ).
Further polymorphisms analyses were performed in germ-line DNA extracted from blood samples of 340 patients, including 247 treated with the four-drug regimens cisplatindocetaxel-capecitabine-gemcitabine (PDXG) and cisplatin-epirubicin-capecitabinegemcitabine (PEXG or ECGemCap) regimens, and 93 treated with gemcitabine (Supplemental Table S1 ). In these two larger cohorts we already performed several stratified analyses of outcome according to chemotherapy regimens and clinical variables [17, 18] , but no tissues were available for studies on EZH2 mRNA and protein levels.
All the eligible subjects were chemo-naive patients with cytologically or histologically proven stage-III or IV PDAC, treated in four hospitals (Supplemental Table S2 ). The study was approved by local Ethic Committees.
Analysis of mRNA/protein expression and genotypes
Genomic RNA and DNA were extracted from tissues and blood samples using the QIAmp Kits according to the manufacturer's protocol (Qiagen, San Diego, CA). EZH2 mRNA values were evaluated by quantitative-PCR, and expressed as arbitrary units (a.u.) normalized to β-actin [7] . EZH2 rs3757441 and rs6950683 genotyping was performed with specific primers/probes (Supplemental Table S3 ) using the ABI-PRISM instrument for Taqman-based-PCR reactions, as described previously [17] . The concordance of these polymorphisms in tumor and germ-line DNA was studied in 25 paired samples of DNA extracted from PDAC and blood of the second cohort of patients, showing identical interindividual genotypes between normal and malignant tissues. No discrepancies were also observed in the samples analyzed in duplicate (approximately 15%), and all the genotyping data were included in the final analysis
The correlation between mRNA and protein expression was firstly evaluated in 20 selected cases of the first cohort of patients, where protein expression was studied using a specific antibody against EZH2 (Abcam-ab109398, 1:30 dilution), with the avidin-biotin-peroxidase complex technique (Vectastain ABC Kit, Vector laboratories, Burlingame, CA). Sections were reviewed by two researchers blinded to genetic data, who scored the immunostaining on the basis of staining intensities and number of stained cells (H-score), as described in the Supplemental Table S4 .
Then, we evaluated EZH2 protein expression in the second cohort, using a Tissue Microarray (TMA), with 4 different tumor areas for each patient, constructed with core tissue biopsies (diameter 1 mm) with the TMA Grand Master instrument (3DHistech, Budapest, Hungary).
Analysis of miRNA-101 expression
EZH2 expression can be regulated by mechanisms other than SNPs, and regulation of EZH2 by miR-101 has been already reported in PDAC [19] . Therefore, we performed a pilot study on the expression of this miRNA using the remaining RNA of 25 cases from the first cohort of PDAC patients, including the 20 cases with data on EZH2 protein expression.
RNA (10 ng) was reverse transcribed and the resulting cDNA was amplified using the specific TaqMan®-MicroRNA-assays (Applied Biosystems, Forster City, CA) for miR-101 and RNU6 (Assay-ID 002253 and 001093, respectively). The PCR reactions were performed as described previously [20] . Specimens were amplified in duplicate with appropriate non-template controls. Amplification data were normalized to RNU6 expression and quantification of relative expression (reported as arbitrary units [a.u.]) was performed using the ΔCt method.
Statistics
Demographic and clinical information was obtained from medical records. Overall survival (OS) and progression-free survival (PFS) were analyzed from the day of treatment start to the end point (death/progression or censoring) according to Kaplan-Meier method, and compared by log-rank test. Correlation with EZH2 genotypes was evaluated grouping patients according to the 3 genotypes and collapsing homozygous and heterozygous genotypes when they had the same direction of effect, as described previously [18] . Data were analyzed using SPSS-20 software (IBM, Chicago, IL). All the analyses were twosided and statistical significance was set at P<0.05. A P value between 0.05 to 0.10 was considered as a trend toward significance.
Results
EZH2 mRNA correlates with survival, rs6950683 polymorphism and protein expression
EZH2 mRNA expression was detectable in all microdissected samples. The RNA yield ranged between 27 and 112 ng/, and 250 ng were used for cDNA synthesis, obtaining Threshold Cycle (Ct) values between 26 and 30 in the Taqman-based-PCR reactions. Moreover, quantitative-PCR data showed a variability coefficient of Ct always lower than 2% of mean values.
Patients were categorized into two subgroups with respect to the median mRNA expression and evaluated for clinical outcome after gemcitabine chemotherapy (Fig. 1A) . The high EZH2 expression group had a significantly poorer prognosis (median OS of 6.7 months, 95% CI, 5.3-8.0, compared with 9.4 months, 95% CI, 1.6-17.2, in patients with low expression levels). Similar results were observed for PFS, with median values of 4.4, 95% CI, 3.2-5.2, versus 8.4 months, 95% CI, 5.5-11.3 (P=0.04), in patients with high and low EZH2 expression, respectively. Remarkably, EZH2 expression profile was lower in grade-1/2 (N=13) than grade-3 (N=19) tumors (0.39±0.16 vs. 0.64±0.26 a.u., respectively, P<0.05 in the Wilcoxon rank sum test). In contrast, no difference was detected according to other clinicopathological parameters ( Table 1 ). The plot in Fig 1B shows the variability of gene expression across the cohort of 32 patients subjected to transcription analysis according to EZH2 polymorphisms. The rs6950683 C/C genotype was associated with a significantly higher EZH2 expression, and patients carrying this genotype (N=17) had a OS of 6.7 months, 95% CI, 5.5-7.9, versus 12.5 months, 95% CI, 7.1-17.9 in patients (N=15) harbouring the C/T-T/T genotypes (Fig.1C) . Notably patients with the C/T genotype (N=13) had an intermediate OS (12.5 months, 95% CI, 3.0-13.9), but no further statistical analysis was performed on these subgroups because of the lack of power caused by the low number of cases. Similarly, we did not perform multivariate analyses or additional stratified analyses according to clinical variables.
Immunohistochemistry revealed a variable protein expression, related to the mRNA expression ( Fig.2A) . Indeed, the tissues characterized by high EZH2 mRNA expression, presented a strong and diffuse staining of the EZH2 protein ( Fig.2A, upper panel) , while the tissues with low EZH2 expression had only few scattered positive cells with a weak nuclear staining ( Fig.2A, lower panel) . Additional analysis of EZH2 protein expression was performed on tumor tissues from 25 metastatic PDAC patients collected in a TMA (Fig.3A) , showing that low EZH2 protein expression correlated with longer OS (10.4 months, 95% CI, 7.4-13.6, vs. 3.0 months, 95% CI, 2.5-3.5, P=0.022, Fig.3A) . The rs6950683 C/C SNP was significantly associated with higher EZH2 protein expression (P=0.003, Fig.3B ). Patients carrying this genotype (N=15) had a median OS of 4.0 months, 95% CI, 2.2-8.4, compared to 9.4 months, 95% CI, 1.9-16.9, of patients (N=10) harbouring the C/T-T/T genotypes (P=0.063, Fig.3C ).
EZH2 polymorphisms and outcome in the validation cohorts
The shorter median OS observed in patients with the rs6950683 C/C genotype in our first two cohorts (with P-values indicating a trend toward a significant difference), as well as the possible correlation of rs6950683 with EZH2 expression, prompted additional pharmacogenetic studies in two larger "validation" cohorts (Table 2) . Genotyping was successfully carried out in all these samples.
Although the purpose of this analysis was not to perform a case-control study, we compared the baseline demographic characteristics, and in the first cohort of patients treated with [18] .
gemcitabine-monotherapy we observed a significantly higher percentage of old patients (age>65 years, P=0.008), but no significant differences were found for gender, performance status (PS), stage or allelic frequencies across series (Supplemental Table S1 ). However, patients treated with the polychemotherapeutic regimens had significantly longer OS, as reported previously [18] .
No correlations were detected between genotypes and clinicopathological parameters (data not shown). Similarly, no significant differences were observed in OS for EZH2 polymorphisms in the "gemcitabine monotherapy" and "PDXG, PEXG and EC-GemCap" cohorts ( Table 2) .
MiR-101 expression correlates with EZH2 protein expression and clinical outcome
miR-101 binds the EZH2 3'-UTR at two sites (Fig. 4A) , and was recently shown to interact with EZH2 in several types of cancer [21] . Therefore, we evaluated miR-101 expression levels in 25 cases of the first cohort of PDACs. These patients were categorized according to median expression value, according to the Gaussian distribution of the expression values of this miRNA (data not shown). Remarkably, we observed a significant inverse relationship (P=0.004) between the expression of miR-101 and the expression of EZH2 (Fig. 4B ). 
Discussion
This is the first study supporting a role for EZH2 as a novel prognostic factor in advanced PDAC patients treated with gemcitabine. Moreover we demonstrated that EZH2 mRNA expression correlated with protein expression and tumor grading.
Previous findings reported that nuclear accumulation of EZH2 was associated with increased invasiveness and poor prognosis in radically-resected patients [3] . Several studies showed that more advanced/malignant pancreatic tumors expressed higher levels of EZH2 [22] . In an analysis of Oncomine databases, two datasets on PDAC showed significantly increased levels of EZH2 in PDAC compared to normal pancreas tissues, as reported in the supplemental Figure S1 [23]. However, in 38 Endoscopic-Ultrasound/Fine-NeedleAspiration samples the staining intensity of EZH2 did not differ in moderately and poorlydifferentiated PDACs [24] . These controversial data might be explained by technical issues such as the limited sampling and the heterogeneity of PDAC specimens that we enriched for tumor cell content by laser-microdissection. Still, more studies are difficult to perform because of the very small amount of tissue available from most advanced PDAC patients. Therefore we evaluated candidate polymorphisms, and found that the C/T and T/T variants of rs6950683 were associated with a lower expression of EZH2. These results might explain the protective role of these genotypes in lung and hepatocellular cancers [9, 14] . Conversely, no correlation was observed with the rs3757441 polymorphism, which was previously associated with outcome in colorectal cancer patients treated with first-line 5-fluorouracil, folinic acid, irinotecan (FOLFIRI) with or without bevacizumab [10] [11] , suggesting that its prognostic role might be tumor specific.
Encouraged by the discovery of a trend toward a significant association of the rs6950683 polymorphism with survival in the first two cohorts of gemcitabine-treated patients, we tested its clinical impact in two larger homogeneous cohorts. These cohorts included patients treated with gemcitabine-alone and with polychemotherapeutic regimens from a multicentric series, to evaluate possible treatment-related effects.
Unfortunately, no correlation with outcome was observed in both cohorts. This lack of correlation might be explained by several factors, including first of all the small sample size of the first two cohorts, However, no data was available of EZH2 expression in the two larger cohorts, and in these cohorts we could not evaluate the association between our candidate SNPs and expression, or expression with survival.
Our candidate SNPs were selected according to previous studies, but they are in linkage disequilibrium with other EZH2 polymorphisms [9] , which might play a more determinant role. Although EZH2 mutations have not yet been reported in PDAC, we cannot exclude that such somatic alterations might occur [22] , affecting EZH2 expression and function in tumor tissues, regardless of its genotype. A recent study demonstrated the pivotal role of EZH2 during the suppression of miR-218 and revealed a new silencing mechanism involving EZH2-induced de novo heterochromatinization in PDAC biology [25] . This heterochromatin induction at miR-218 promoter adds an extra dimension to EZH2-mediated aberrant epigenetic effects in PDAC, supporting further analyses on functional targets of miR-218, such as UDP-glycosyltransferase-8 (UGT8), and vesicular, overexpressed in cancer, prosurvival protein-1 (VOPP1), to dissect the role of EZH2. Similarly, several previous studies suggested the key role of miR-101 in the regulation of EZH2 expression [19] [20] [21] . This was confirmed in our pilot analysis in PDAC tissues of the first cohort of patients, and should prompt future studies on miRNAs affecting EZH2 expression in larger cohorts of patients.
A major strength of the present study is that it was performed on several cohorts of PDAC patients, including patients from multicenter studies, who were all treated with upfront chemotherapy. Conversely, the main limitations of this study include the retrospective explorative study design, the modest sample size and lack of multivariate analysis of the first two cohorts, and the possible confounding influence of drug-combinations on the treatment-SNP effects. Recent preclinical data supported a key role of EZH2 in the sensitivity of PDAC cells to gemcitabine [7] , but several studies reported a general prognostic role of EZH2, independent from the therapeutic strategy [22] . The planning of randomized studies with a control arm of patients treated with other regimens, such as FOLFIRINOX, and the comparison of the survival stratified by genotype would be the only way to establish the specific predictive role of EZH2 for the activity of gemcitabine.
Conclusion and future perspective.
EZH2 expression emerged as a prognostic factor for locally-advanced/metastatic PDAC, but candidate polymorphisms could not predict outcome. Other factors involved in the EZH2-oncogenic pathways or chemoresistance and detectable in accessible samples sources, such as miRNA enriched tumor-derived exosomes in peripheral blood [26] , should be investigated in order to improve the clinical management of advanced PDAC patients.
Executive summary
Introduction

Pancreatic cancer (PDAC) is a major unsolved health problem. Most patients present with advanced disease at diagnosis, and identification of key factors that play a critical role in chemoresistance should offer room for treatment optimization  EZH2 is becoming increasingly acknowledged as a prognostic biomarker in radicallyresected PDAC patients, and EZH2 is also an important factor in PDAC cell chemoresistance to gemcitabine  Single nucleotide polymorphisms (SNP) in EZH2 have been correlated with lung cancer risk and colorectal cancer prognosis, possibly affecting EZH2 expression
The aim of the current study was to evaluate the correlation between these candidate SNPs and EZH2 expression, as well as with clinical outcome in 4 cohorts of PDAC patients treated with gemcitabine or with polychemotherapeutic regimens.
Pharmacogenetics of EZH2 in PDAC patients

In a cohort of PDAC laser-microdissected specimens EZH2 mRNA levels correlated with survival: the high EZH2 expression group had a significantly poorer prognosis. Similar results were observed for PFS.
Immunohistochemistry revealed a correlation between EZH2 mRNA and protein expression in resected PDACs, and EZH2 expression correlated with OS in 2 cohorts of locally-advanced/metastatic patients treated with gemcitabine.
In these cohorts the rs6950683 C/C genotype was associated with a significantly higher EZH2 expression, and patients carrying this genotype had a trend towards a significantly shorter OS.
However, no significant differences were observed in OS for EZH2 polymorphisms in two larger cohorts of patients treated with gemcitabine and with polychemotherapeutic regimens.
Conclusions and future perspectives

The results of the present study demonstrated the prognostic role of EZH2 in advanced PDAC patients treated with gemcitabine. Moreover we demonstrated that EZH2 mRNA expression correlated with protein expression and tumor grading.  Although the rs6950683 C/C genotype correlated with EZH2 expression, no correlation with outcome was observed in 2 validation cohorts. This lack of correlation might be explained by several factors including the modulation of EZH2 expression by miRNA-101, which was observed in the first cohort of patients.
Since PDAC is such a dismal disease, any biomarker that can help to better stratify patients might have crucial clinical applications.  Other factors involved in the regulation of EZH2 expression/activity and detectable in accessible samples sources should be investigated in order to improve the clinical management of advanced PDAC patients.
Supporting information
Analysis of RNA quality
The Nanodrop spectrophotometer allowed us to measure in the majority of our samples optimal values for the RNA concentration (>50 ng/μL) and purity, as estimated with the ratio of the absorbance at 260 and 280nm (A260/280 ratio, in the 1.6-2.0 range). However, since the RNA degradation in tissues may affect analysis of mRNA expression, we performed additional analyses on the integrity of RNA, using the microcapillary electrophoretic RNA separation with the Agilent 2100 Bioanalyzer (NanoChip kit, Agilent, Agilent Technologies, Palo Alto, CA) in 10 randomly chosen FFPE samples. The RNA Integration Numbers (RIN) values in 70% of these samples were above 8, supporting the reliability of our results.
Laser-microdissection
Neoplastic cells were then dissected using the Leica LMD6500 instrument (Leica, Wetzlar, Germany). Because of the long experience of our laboratory with this method, there was no difficulty in selecting areas with morphological defined cancer cells (Ref.#1). The precision of the narrow focus of the laser beam resulted in the capture of individual cells with high degree of accuracy. However, to validate the purity of microdissected cell populations, we also evaluated the mRNA levels of keratin-7, in 10 cases where RNA extraction was obtained from the whole tumor, and in the respective laser-microdissected specimens. Expression analysis was performed with specific primers (Hs00559840_m1, Applied Biosystems), using Taqman quantitative PCR, as described (Ref.#2). In agreement with previous data (Ref.#3), the expression of keratin-7 was significantly higher in the lasermicrodissected vs. the non-laser-microdissected samples (P<0.001), and the purity percentage calculated with the ratio between gene expression in the microdissected samples versus the non-microdissected specimens was 90%. 
